Company intelligence / Profile preview
Sydnexis Inc.
San Diego/Del Mar, California, United Statessydnexis.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Sydnexis has completed a three-year Phase 3 clinical trial (STAR Study) evaluating its proprietary low-dose atropine formulation (SYD-101) to slow the progression of pediatric myopia. The FDA has accepted their NDA with a PDUFA target action date of October 23, 2025[5].
- Therapeutic areas
- Ophthalmology
- Modalities
- Small molecules (low-dose atropine formulation)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Sydnexis Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sydnexis Inc..